Bio-Rad anti-idiotypic antibodies
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity). The Company has also launched its first anti-Fc mutation antibody range, targeting drugs containing YTE mutations.
Bio-Rad’s range of highly specific, high-affinity, non-animal derived antibodies are suitable for use in preclinical and clinical pharmacokinetic (PK) and anti-drug antibody (ADA) assays, supporting therapeutic drug monitoring for biologic and biosimilar products. The addition of an antibody specific to dulaglutide marks Bio-Rad’s first antibody against a GLP-1 receptor agonist drug.
The launch of the anti-Fc mutation antibody range now enables the selective detection of YTE-modified therapeutics via the recognition of YTE triple substitutions (M252Y, S254T, and T256E) in the Fc region of human IgG1 antibodies—a modification shown to extend antibody half-life compared to wild-type IgG. The ready-made antibodies are suitable for the development of PK bridging ELISAs to measure free drug concentration in serum.
“With over 350 antibodies of more than 50 different specificities, Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies offers researchers greater flexibility to develop selective, sensitive, and reliable bioanalytical assays,” said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad Laboratories. “The launch of our first anti-Fc mutation range alongside a new range of anti-biotherapeutic antibodies, including our first against a drug acting as a GLP-1 receptor agonist, marks a significant step beyond classical anti-IDs, underscoring how our technology is adaptable to any new drug format and our commitment to drive innovation across antibody drug discovery.”
Learn more about Bio-Rad's anti-idiotypic antibodies at bio-rad-antibodies.com/antiidspr and anti-FC mutation antibodies at bio-rad-antibodies.com/ytemutpr.
Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. All trademarks used herein are the property of their respective owner. © 2026 Bio-Rad Laboratories, Inc.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,400 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our commitment to drive innovation across antibody drug discovery, our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
Katrina_academia@bio-rad.com
Zyme Communications
Dr. Maria Spyrou
maria.spyrou@zymecommunications.com
To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com.
To view our privacy policy, click here.